Results 61 to 70 of about 178,847 (197)

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Advanced Healthcare Materials, EarlyView.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj, Xilal Y. Rima, Kim T. Nguyen, Courtney Culkins, Nana Boateng, Jacob Doon‐Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, Ajeet Pal Singh, Dharti Shantaram, Anastasiia Amari, Mangesh D. Hade, Nicholas R. Merriam, Zachary D. Schultz, Scott Q. Harper, Nizar Y. Saad, Setty M. Magaña, Willa A. Hsueh, Rachel E. Kopec, Blaise R. Kimmel, Andre F. Palmer, Eduardo Reátegui   +23 more
wiley   +1 more source

Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment

Advanced Healthcare Materials, EarlyView.
Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley   +1 more source

Ion‐Reconfigurable “N”‐Shaped Antiambipolar Behavior in Organic Electrochemical Transistors

Advanced Materials, EarlyView.
A unique N‐shaped negative differential transconductance (NDT) characteristics is demonstrated in single‐polymer organic electrochemical transistors through a sequential doping–redox–doping process driven by iodide ions. This redox‐driven mechanism enables low‐voltage, ion‐controlled reconfigurability and tunable current modulation, allowing seamless ...
Debdatta Panigrahi, Daniele Zucchelli, Zeinab Hamid, Christina Kousseff, Arup Sarkar, Aristea Pavlou, Zhitian Ling, Somayeh Kashani, Iain McCulloch, Paul W. M. Blom, Fabrizio Torricelli, Paschalis Gkoupidenis   +11 more
wiley   +1 more source

Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy

Advanced Materials, EarlyView.
Co‐encapsulation of p53 mRNA and the small molecule ciclopirox within a lipid nanoparticle yields an all‐in‐one chemoimmunotherapy for oral squamous cell carcinoma. The platform engages caspase‐driven apoptosis in cancer cells while repolarizing tumor‐associated macrophages, achieving tumor reduction in both p53‐susceptible and p53‐resistant models and
Marshall S. Padilla, Jacqueline J. Li, Qunzhou Zhang, Korey Patwari, Shihong Shi, Hannah M. Yamagata, Ryann A. Joseph, Briyanna N. Hymms, Sridatta V. Teerdhala, Emily Fitzgerald, Ori Z. Chalom, Kushol Gupta, Mohamad‐Gabriel Alameh, Drew Weissman, Anh D. Le, Michael J. Mitchell   +15 more
wiley   +1 more source

GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer

Heliyon
The programmed death-ligand 1 (PD-L1) on the surface of tumor cells binds to the receptor programmed cell death protein 1 (PD-1) on effector T cells, thereby inhibiting the anti-tumor immune response. Immune checkpoint blockade (ICB) therapy targeting PD-
Xue Sun, Mingen Lin, Ziyin Tian, Yan Ma, Lei Lv   +4 more
doaj   +1 more source

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

Frontiers in Immunology, 2017
The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the ...
Rachel M. Gibbons Johnson, Haidong Dong, Haidong Dong   +2 more
doaj   +1 more source

Reprogramming the Immunosuppressive Microenvironment in Triple‐Negative Breast Cancer via FAP‐Targeted Nanoprobes for Multimodal Imaging and Photothermal Therapy

Advanced Materials, EarlyView.
Targeting cancer‐associated fibroblasts (CAFs) with fibroblast activation protein (FAP)‐directed nanoprobes for multimodal imaging and photothermal remodeling of the immunosuppressive microenvironment to enhance immunotherapy in triple‐negative breast cancer (TNBC).
Ling Zhan, Yanhong Chen, Jingjing Hu, Chunting Wang, Huanhuan Liu, Defan Yao, Dengbin Wang   +6 more
wiley   +1 more source

A Chemical Framework for Engineering Extracellular Vesicles’ Biointerface to Advance Precision Therapeutics

Advanced Materials, EarlyView.
Extracellular vesicles (EVs) are cell‐derived nanoparticles that mediate intercellular communication through their dynamic biointerfaces. Owing to their intrinsic biological functions, EVs have emerged as promising platforms for biomedical applications.
Leila Pourtalebi Jahromi, Felix Geng, Jan‐Noël Frenzke, Gregor Fuhrmann   +3 more
wiley   +1 more source

Ionizable Lipid‐Dependent Optimization of Steroid Lipid Nanoparticles With Tunable Immunomodulatory Properties

Advanced Materials, EarlyView.
A novel engineering strategy that establishes material design principles for incorporating anti‐inflammatory steroids into lipid nanoparticles to reduce LNP‐induced inflammation while retaining mRNA delivery. Results are validated in vitro and in three animal models of inflammation and autoimmunity in vivo.
Ajay S. Thatte, Benjamin E. Nachod, Julia Baena, Jenna Muscat‐Rivera, Lesley Chaboub, Hannah C. Safford, Hannah C. Geisler, Hannah M. Yamagata, Melgious J. Y. Ang, Michael Kegel, Alexandre Poirier, Elaine R. Tong, Zhe Zhong, Qiangqiang Shi, Jinjin Wang, Elisa Battistini, Ye Zeng, Alex G. Hamilton, Kelsey L. Swingle, Drew Weissman, Jilian R. Melamed, Michael J. Mitchell   +21 more
wiley   +1 more source

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell & Bioscience, 2018
Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained
Fei Tang, Pan Zheng
doaj   +1 more source